SM
CRSP icon

SG3 Management’s CRISPR Therapeutics CRSP Stock Holding History

SG3 Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$87.4K – 1078
2021
Q3 		$112K Buy
+1,000
New +$126K ﹤0.01% 851
2021
Q2 		– Sell
-17,500
Closed -$2.13M – 1088
2021
Q1 		$2.13M Buy
+17,500
New +$2.64M 0.05% 391

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SG3 Management's CRSP Position: Q4 2021 in Review

SG3 Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 1,000 shares — an estimated $87.4K sold.

SG3 Management first reported a position in CRSP in Q1 2021 and held it in 2 quarters. The position peaked at $2.13M in Q1 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • SG3 Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 1,000 CRISPR Therapeutics shares in Q4 2021, an estimated $87.4K.
  • SG3 Management first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 2 quarters.
  • SG3 Management's CRISPR Therapeutics position peaked at $2.13M in Q1 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.